Patient description: A 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. She is an obese woman with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones, biliary sludge and CBD stones. The smallest stone is 14mm.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Morbid Obesity Subjects BMI obese groups: subject must have a BMI > 40 kg/m2 at the time of non-obese group: subject must have a BMI ≥18.5 and < 25kg/m2 at the time of inclusion. 2. Subject is at least 18 of age on the day of screening and not older than 65 years of age on the day of dosing; 3. If a woman, is neither pregnant nor able to become pregnant and is not nursing an infant; 4. Subject is able and willing to sign the Informed Consent before screening evaluations. For the non-obese subjects the following additional  apply: 5. Subject is in good age-appropriate health condition as established by medical history, physical examination, electrocardiography, results of biochemistry, hematology and urinalysis testing within 4 weeks prior to study drug administration. Results of biochemistry, hematology and urinalysis testing should be within the laboratory's reference ranges. If laboratory results are not within the reference ranges, the subject is included based on the investigator's judgment that the observed deviations are not clinically relevant. This should be clearly recorded; 6. Subject has a normal blood pressure and pulse rate, determined by the investigator; 7. Subject does not smoke more than 10 cigarettes, 2 cigars, or 2 pipes per day for at least 3 months prior to study drug administration Documented history of sensitivity to medicinal products or excipients similar to those found in the micafungin preparation; 2. History of, or known abuse of drugs, alcohol or solvents (up until a maximum of three months before study drug administration); 3. Inability to understand the nature of the trial and the procedures required; 4. Use of medication that has known interaction with study drug as determined by the investigator up to 4 weeks prior to study drug administration. For the non-obese subjects the following additional apply: 5. Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs or clinical laboratory determinations; 6. Clinical relevant liver enzymes (alkaline phosphatase, alanine aminotransferase, aspartate transaminase) abnormalities at screening; 7. Donation of blood or plasma to a blood bank or in a clinical study (except a screening visit) within 4 weeks prior to study drug administration; 8. Blood transfusion within 8 weeks prior to study drug administration; 9. Inability to be venipunctured and/or tolerate venous access; 10. Relevant history or presence of pulmonary disorders (especially COPD), cardiovascular disorders, neurological disorders (especially seizures and migraine), psychiatric disorders, gastro-intestinal disorders, renal disorders, hepatic disorders (Child-Pugh B or C), hormonal disorders (especially diabetes mellitus), coagulation disorders; 11. Any other sound medical, psychiatric and/or social reason as determined by the investigator